| Type | Publicly traded |
|---|---|
| Industry | Biomedicine |
| Headquarters | Dallas, Texas, USA |
| Products | MuGard |
| Website | http://www.accesspharma.com |
Access Pharmaceuticals, Inc. is a biopharmaceutical company based in Dallas, Texas.[1] It uses nanotechnology to modify existing medications to improve their efficacy and tolerance.
As of June 2008, Access has one product approved by the Food and Drug Administration (FDA), namely MuGard for the management of oral mucositis.[1] In September 2010, Access received its first U.S. purchase order for MuGard and as of fall 2010 continued to receive more and more prescriptions for the product. Also, two products are in clinical trials, ProLindac, a drug that contains the DACH-platinum oxaliplatin (an anti-ovarian cancer agent)[2], and a product with phenylbutyrate, a HDAC inhibitor.
In 2009 the company reported on preclinical studies of its agent Angiolix, a monoclonal antibody that binds to lactadherin and inhibits angiogenesis.[3]